2024
Aldehydes alter TGF-β signaling and induce obesity and cancer
Yang X, Bhowmick K, Rao S, Xiang X, Ohshiro K, Amdur R, Hassan M, Mohammad T, Crandall K, Cifani P, Shetty K, Lyons S, Merrill J, Vegesna A, John S, Latham P, Crawford J, Mishra B, Dasarathy S, Wang X, Yu H, Wang Z, Huang H, Krainer A, Mishra L. Aldehydes alter TGF-β signaling and induce obesity and cancer. Cell Reports 2024, 43: 114676. PMID: 39217614, DOI: 10.1016/j.celrep.2024.114676.Peer-Reviewed Original ResearchAldehyde dehydrogenase 2Small interfering RNADisease progression to cancerPro-oncogenic phenotypeTGF-bProgression to cancerGrowth factor BTGF-b signalingHuman metabolic syndromeSteatotic liver diseasePotential therapeutic targetMetabolic syndromePro-fibroticInduce obesityTherapeutic inhibitionLiver diseaseCurrent treatmentSmad3 signalingGlucose handlingTherapeutic targetFunctional phenotypeDehydrogenase 2Improve glucose handlingSPTBN1ObesitySu1127 MYOSTATIN CONTRIBUTES TO ALTERATIONS IN METABOLIC PATHWAYS AND MUSCLE ATROPHY IN MASH AND HCC AND IS A PROMISING BIOMARKER WITH METABOLIC MARKER PKM2 FOR RISK STRATIFICATION OF HCC
Bhowmick K, Xiang X, Ohshiro K, Amdur R, Yang X, Wong L, Shetty K, Latham P, Lau L, Crandall K, Cifani P, Cacaj F, Mishra B, Dasarathy S, Wang X, Yu H, Wang Z, Krainer A, Satapathy S, Crawford J, Mishra L. Su1127 MYOSTATIN CONTRIBUTES TO ALTERATIONS IN METABOLIC PATHWAYS AND MUSCLE ATROPHY IN MASH AND HCC AND IS A PROMISING BIOMARKER WITH METABOLIC MARKER PKM2 FOR RISK STRATIFICATION OF HCC. Gastroenterology 2024, 166: s-666. DOI: 10.1016/s0016-5085(24)01982-6.Peer-Reviewed Original ResearchDetection of hepatocellular carcinoma methylation markers in salivary DNA
Mezzacappa C, Wang Z, Lu L, Risch H, Taddei T, Yu H. Detection of hepatocellular carcinoma methylation markers in salivary DNA. Bioscience Reports 2024, 44: bsr20232063. PMID: 38457142, PMCID: PMC10958141, DOI: 10.1042/bsr20232063.Peer-Reviewed Original ResearchHepatocellular carcinoma screeningCase patientsHepatocellular carcinomaControl subjectsDiagnosis of hepatocellular carcinomaAssociated with hepatocellular carcinomaScreening testSalivary DNASaliva-based testCpG sitesStudy of risk factorsSalivary DNA methylationDNA methylationViral hepatitisCirculating DNAAlterations to DNA methylationRisk factorsMethylation markersPatientsRegulation of cell cycle progressionBlood samplesCell cycle progressionAffected individualsAlternative to blood samplingMultiple comparisonsMechanistically based blood proteomic markers in the TGF-β pathway stratify risk of hepatocellular cancer in patients with cirrhosis.
Xiang X, Bhowmick K, Shetty K, Ohshiro K, Yang X, Wong L, Yu H, Latham P, Satapathy S, Brennan C, Dima R, Chambwe N, Sharifova G, Cacaj F, John S, Crawford J, Huang H, Dasarathy S, Krainer A, He A, Amdur R, Mishra L. Mechanistically based blood proteomic markers in the TGF-β pathway stratify risk of hepatocellular cancer in patients with cirrhosis. Genes & Cancer 2024, 15: 1-14. PMID: 38323119, PMCID: PMC10843195, DOI: 10.18632/genesandcancer.234.Peer-Reviewed Original ResearchHepatocellular carcinomaPyruvate kinase M2TGF-bPresence of hepatocellular carcinomaEarly detection of HCCRisk of hepatocellular cancerDetection of hepatocellular carcinomaAdvanced incurable stageRisk-stratifying biomarkersTGF-B pathwayAssociated with hepatocellular carcinomaProteomic markersEarly detectionBiologically relevant markersIncurable stageBlood-based biomarkersHepatocellular cancerRisk stratificationStratify riskNon-HCCClinical variablesBlood levelsLiver diseaseAnimal modelsBiological role
2023
Machine learning-based cluster analysis of immune cell subtypes and breast cancer survival
Wang Z, Katsaros D, Wang J, Biglio N, Hernandez B, Fei P, Lu L, Risch H, Yu H. Machine learning-based cluster analysis of immune cell subtypes and breast cancer survival. Scientific Reports 2023, 13: 18962. PMID: 37923775, PMCID: PMC10624674, DOI: 10.1038/s41598-023-45932-4.Peer-Reviewed Original ResearchConceptsImmune cell clustersT cellsHost immunityImmune cellsUnsupervised hierarchical clusteringImmune responseCD8-positive T cellsMemory CD4 T cellsCox regression survival analysisRegulatory T cellsPositive T cellsCD4 T cellsDifferent immune cellsDistinct immune responsesBreast cancer survivalImmune cell subtypesMemory B cellsImmune cell typesRegression survival analysisCell clustersBreast cancer progressionT cell receptor signalingCytokine stormOverall survivalFavorable survivalHula as a physical activity and social support intervention for sustained activity in female breast and gynecologic cancer survivors
Bantum E, Yamada P, Makolo T, Yu H, Pagano I, Subia N, Walsh C, Loo L. Hula as a physical activity and social support intervention for sustained activity in female breast and gynecologic cancer survivors. Frontiers In Psychology 2023, 14: 1190532. PMID: 37941759, PMCID: PMC10629222, DOI: 10.3389/fpsyg.2023.1190532.Peer-Reviewed Original ResearchPhysical activityCancer survivorsMaintenance of physical activityPhysical activity improves healthPre-and post-interventionQuality of life of cancer survivorsGynecologic cancer survivorsBenefits of social supportModerate physical activitySocial support interventionsSustained physical activityLife of cancer survivorsRandomized wait-listSupport interventionsPost-interventionIntervention groupNational Cancer InstituteWaist circumferencePsychosocial dataSupport groupsSocial supportNative HawaiiansPsychosocial functioningFemale breastImprove enjoymentElucidating the role of blood metabolites on pancreatic cancer risk using two‐sample Mendelian randomization analysis
Zhong H, Liu S, Zhu J, Xu T, Yu H, Wu L. Elucidating the role of blood metabolites on pancreatic cancer risk using two‐sample Mendelian randomization analysis. International Journal Of Cancer 2023, 154: 852-862. PMID: 37860916, PMCID: PMC10843029, DOI: 10.1002/ijc.34771.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaPDAC riskBlood metabolitesGenetic instrumentsTwo-sample Mendelian randomization studyPancreatic Cancer Case-Control ConsortiumEPIC-Norfolk cohortPancreatic cancer riskEuropean ancestryPancreatic Cancer Cohort ConsortiumPotential side effectsCanadian Longitudinal StudyAssociations of metabolitesMendelian randomization studyTwo-sample Mendelian randomization (MR) analysisGenome-wide association studiesMendelian randomization analysisFatal malignancyDuctal adenocarcinomaCancer riskPDAC casesSide effectsAging CohortMetabolite biomarkersRandomization studyNight shift work, sleep duration and endometrial cancer risk: A pooled analysis from the Epidemiology of Endometrial Cancer Consortium (E2C2)
Frias-Gomez J, Alemany L, Benavente Y, Clarke M, de Francisco J, De Vivo I, Du M, Goodman M, Lacey J, Liao L, Lipworth L, Lu L, Merritt M, Michels K, O'Connell K, Paytubi S, Pelegrina B, Peremiquel-Trillas P, Petruzella S, Ponce J, Risch H, Setiawan V, Schouten L, Shu X, Trabert B, Van den Brandt P, Wentzensen N, Wilkens L, Yu H, Costas L. Night shift work, sleep duration and endometrial cancer risk: A pooled analysis from the Epidemiology of Endometrial Cancer Consortium (E2C2). Sleep Medicine Reviews 2023, 72: 101848. PMID: 37716022, PMCID: PMC10840870, DOI: 10.1016/j.smrv.2023.101848.Peer-Reviewed Original ResearchConceptsNight shift workEndometrial Cancer ConsortiumEndometrial cancer riskEndometrial cancerSleep durationShift workPostmenopausal womenPooled analysisInverse associationOdds ratioCancer riskCancer ConsortiumNon-significant inverse associationStudy-specific odds ratiosEndometrial cancer casesStrong risk factorConfidence intervalsLong sleep durationDaily sleep durationObese womenRisk factorsCancer casesLogistic regressionIndividual dataCancerIdentification of blood protein biomarkers associated with prostate cancer risk using genetic prediction models: analysis of over 140,000 subjects
Zhong H, Zhu J, Liu S, Ghoneim D, Surendran P, Liu T, Fahle S, Butterworth A, Alam A, Deng H, Yu H, Wu C, Wu L. Identification of blood protein biomarkers associated with prostate cancer risk using genetic prediction models: analysis of over 140,000 subjects. Human Molecular Genetics 2023, 32: 3181-3193. PMID: 37622920, PMCID: PMC10630250, DOI: 10.1093/hmg/ddad139.Peer-Reviewed Original ResearchConceptsPCa riskProstate cancerHuge public health burdenEtiology of PCaBlood protein biomarkersConventional epidemiologic studiesProstate cancer riskPublic health burdenConventional observational studiesCancer Genome AtlasPCa patientsHealth burdenProtein biomarker candidatesObservational studyEpidemiologic studiesCancer riskTherapeutic strategiesCancer-related pathwaysSignificant associationBiomarker candidatesGenome AtlasProtein levelsDrug repurposingRiskPositive associationGenetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization.
King S, Veliginti S, Brouwers M, Ren Z, Zheng W, Setiawan V, Wilkens L, Shu X, Arslan A, Beane Freeman L, Bracci P, Canzian F, Du M, Gallinger S, Giles G, Goodman P, Haiman C, Kogevinas M, Kooperberg C, LeMarchand L, Neale R, Visvanathan K, White E, Albanes D, Andreotti G, Babic A, Berndt S, Brais L, Brennan P, Buring J, Rabe K, Bamlet W, Chanock S, Fuchs C, Gaziano J, Giovannucci E, Hackert T, Hassan M, Katzke V, Kurtz R, Lee I, Malats N, Murphy N, Oberg A, Orlow I, Porta M, Real F, Rothman N, Sesso H, Silverman D, Thompson I, Wactawski-Wende J, Wang X, Wentzensen N, Yu H, Zeleniuch-Jacquotte A, Yu K, Wolpin B, Duell E, Li D, Hung R, Perdomo S, McCullough M, Freedman N, Patel A, Peters U, Riboli E, Sund M, Tjønneland A, Zhong J, Van Den Eeden S, Kraft P, Risch H, Amundadottir L, Klein A, Stolzenberg-Solomon R, Antwi S. Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization. Cancer Epidemiology Biomarkers & Prevention 2023, 32: 1265-1269. PMID: 37351909, PMCID: PMC10529823, DOI: 10.1158/1055-9965.epi-23-0453.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseasePancreatic cancer riskFatty liver diseasePancreatic cancerCancer riskLiver diseaseGenetic predispositionMendelian randomizationPancreatic Cancer Case-Control ConsortiumConfidence intervalsPancreatic Cancer Cohort ConsortiumPC risk factorsMR methodsRisk factorsGenome-wide association studiesGenetic susceptibilityLogistic regressionCancerMetabolic perturbationsMetabolic conditionsRiskDiseaseGenetic variantsAssociationPredispositionAssociation between use of antihypertensive drugs and the risk of cancer: a population-based cohort study in Shanghai
Wang S, Xie L, Zhuang J, Qian Y, Zhang G, Quan X, Li L, Yu H, Zhang W, Zhao W, Qian B. Association between use of antihypertensive drugs and the risk of cancer: a population-based cohort study in Shanghai. BMC Cancer 2023, 23: 425. PMID: 37165412, PMCID: PMC10173582, DOI: 10.1186/s12885-023-10849-8.Peer-Reviewed Original ResearchConceptsPopulation-based cohort studyTotal cancerAntihypertensive drugsHypertensive patientsCohort studyAntihypertensive medicinesThyroid cancerHigh riskPossible dose-response relationshipAntihypertensive drug administrationCommon antihypertensive drugsRisk of cancerCommunity healthcare centersDose-response relationshipMajor cancer typesAntihypertensive classesCancer casesMAIN OUTCOMECancer riskHealthcare centersDrug AdministrationPatientsSignificant associationCancerCancer typesMulti-omics profiling of papillary thyroid microcarcinoma reveals different somatic mutations and a unique transcriptomic signature
Li Q, Feng T, Zhu T, Zhang W, Qian Y, Zhang H, Zheng X, Li D, Yun X, Zhao J, Li Y, Yu H, Gao M, Qian B. Multi-omics profiling of papillary thyroid microcarcinoma reveals different somatic mutations and a unique transcriptomic signature. Journal Of Translational Medicine 2023, 21: 206. PMID: 36941725, PMCID: PMC10026500, DOI: 10.1186/s12967-023-04045-2.Peer-Reviewed Original ResearchConceptsTCGA patientsPositive thyroglobulin antibodiesPapillary thyroid microcarcinomaNew therapeutic hypothesesUnique transcriptomic signaturesImmune-related genesWhole-exome sequencingImmune interventionPeroxidase antibodiesThyroglobulin antibodiesEtiology of cancerRET fusionsThyroid microcarcinomaTCGA cohortBRAF mutationsPatientsDifferent somatic mutationsMulti-omics profilingLarger studyConclusionsOur findingsResultsIn additionExome sequencingTherapeutic hypothesesTranscriptomic signaturesMolecular landscapeGenetic variants of glucose metabolism and exposure to smoking in African American breast cancer.
Jung S, Papp J, Sobel E, Pellegrini M, Yu H. Genetic variants of glucose metabolism and exposure to smoking in African American breast cancer. Endocrine Related Cancer 2023, 30 PMID: 36705562, PMCID: PMC10095926, DOI: 10.1530/erc-22-0184.Peer-Reviewed Original ResearchConceptsInsulin resistanceBC riskLifestyle factorsSingle nucleotide polymorphismsAA womenRisk genotypesAfrican American postmenopausal womenAfrican-American breast cancerRisk of BCBreast cancer developmentDose-dependent mannerPostmenopausal womenPositive BCPredictive markerRisk factorsFemale hormonesBreast cancerGlucose metabolismMetabolic biomarkersGene-environment interaction analysisSmokingPreventive interventionsCancer developmentWhite womenIndividual single nucleotide polymorphismsAssociation of SNPs in the PAI1 Gene with Disease Recurrence and Clinical Outcome in Bladder Cancer
Murakami K, Furuya H, Hokutan K, Goodison S, Pagano I, Chen R, Shen C, Chan M, Ng C, Kobayashi T, Ogawa O, Miyake M, Thornquist M, Shimizu Y, Hayashi K, Wang Z, Yu H, Rosser C. Association of SNPs in the PAI1 Gene with Disease Recurrence and Clinical Outcome in Bladder Cancer. International Journal Of Molecular Sciences 2023, 24: 4943. PMID: 36902377, PMCID: PMC10003630, DOI: 10.3390/ijms24054943.Peer-Reviewed Original ResearchConceptsPlasminogen activator inhibitor-1Bladder cancerSingle nucleotide polymorphismsMutational statusWorse recurrence-free survivalUntranslated region (UTR) single nucleotide polymorphismRecurrence-free survivalBladder cancer developmentHuman bladder tumorsAssociation of SNPsCommon cancer typesActivator inhibitor-1Anti-apoptotic effectsOverall survivalDisease recurrenceClinical outcomesOverall incidenceBladder tumorsCaucasian patientsIndependent cohortCancer typesCancer developmentCancerInhibitor-1Cellular proliferation
2022
Pathogenesis to management of hepatocellular carcinoma
Da B, Suchman K, Lau L, Rabiee A, He A, Shetty K, Yu H, Wong L, Amdur R, Crawford J, Fox S, Grimaldi G, Shah P, Weinstein J, Bernstein D, Satapathy S, Chambwe N, Xiang X, Mishra L. Pathogenesis to management of hepatocellular carcinoma. Genes & Cancer 2022, 13: 72-87. PMID: 36533190, PMCID: PMC9746873, DOI: 10.18632/genesandcancer.226.Peer-Reviewed Original ResearchHepatocellular carcinomaCommon primary liver cancerEarly-stage hepatocellular carcinomaLiver-directed therapiesPathogenesis of HCCPrimary liver cancerMetastatic hepatocellular carcinomaViable animal modelAdvanced diseaseLiver resectionSystemic therapyPoor prognosisRisk factorsHCC managementHistological classificationLiver cancerNew therapiesAnimal modelsTherapyTissue samplingRelevant biomarkersAlcohol useMolecular targetsCarcinomaPathogenesisDietary omega-3 fatty acids and endometrial cancer risk in the Epidemiology of Endometrial Cancer Consortium: An individual-participant meta-analysis
Brasky T, Hade E, Cohn D, Newton A, Petruzella S, O'Connell K, Bertrand K, Cook L, De Vivo I, Du M, Freudenheim J, Friedenreich C, Goodman M, Gorzelitz J, Ibiebele T, Krogh V, Liao L, Lipworth L, Lu L, McCann S, O'Mara T, Palmer J, Ponte J, Prizment A, Risch H, Sandin S, Schouten L, Setiawan V, Shu X, Trabert B, van den Brandt P, Webb P, Wentzensen N, Wilkens L, Wolk A, Yu H, Neuhouser M. Dietary omega-3 fatty acids and endometrial cancer risk in the Epidemiology of Endometrial Cancer Consortium: An individual-participant meta-analysis. Gynecologic Oncology 2022, 169: 137-146. PMID: 36934308, PMCID: PMC10025515, DOI: 10.1016/j.ygyno.2022.10.015.Peer-Reviewed Original ResearchConceptsEndometrial cancer riskEndometrial Cancer ConsortiumHigh dietary intakeCancer riskDietary intakeObese womenOdds ratioCancer ConsortiumDietary omega-3 fatty acidsOmega-3 fatty acidsEnergy-adjusted quartilesEndometrial cancer casesEndometrial cancer incidenceProspective cohort studyFood frequency questionnaireNormal-weight womenFatty acid intakeAdjusted odds ratioBody mass indexLong-chain omega-3Anti-inflammatory propertiesSubgroup of womenConfidence intervalsCase-control studyTwo-stage individual participant dataAbstract 3378: Targeted serum proteomics identifies a signature for use in multivariable logistic regression modeling to predict HCC
Rao S, Amdur R, Xiyan X, Shetty K, Yu H, Wong L, Jogunoori W, Amin K, Latham P, Mishra L. Abstract 3378: Targeted serum proteomics identifies a signature for use in multivariable logistic regression modeling to predict HCC. Cancer Research 2022, 82: 3378-3378. DOI: 10.1158/1538-7445.am2022-3378.Peer-Reviewed Original ResearchPositive predictive valueMultivariate logistic regressionTargeted serum proteomicsArea under the curveHepatocellular carcinomaReceiver operating characteristicTGF-bAmerican Association for Cancer Research annual meetingsClinical variablesDetect early HCCLogistic regressionEarly stage HCCHigh-throughput proteomic assayPrediction of hepatocellular carcinomaStages of hepatocellular carcinomaTGF-B pathwayFollow-up study of patientsStage hepatocellular carcinomaNon-HCC groupDetect hepatocellular carcinomaHepatocellular carcinoma groupEarly HCCHepatocellular carcinoma patientsSerum proteomeStudy of patientsAbstract 3379: Multi-cohort study shows HCC is associated with a relative regional reduction in TGFBR2 in liver biopsies from patients with cirrhosis
Bhowmick K, Amdur R, Xiang X, Yu H, Wong L, Rao S, He A, Amin K, Zaheer D, Narayan R, Satapathy S, Guha C, Latham P, Shetty K, Gough N, Mishra L. Abstract 3379: Multi-cohort study shows HCC is associated with a relative regional reduction in TGFBR2 in liver biopsies from patients with cirrhosis. Cancer Research 2022, 82: 3379-3379. DOI: 10.1158/1538-7445.am2022-3379.Peer-Reviewed Original ResearchHepatocellular carcinomaLiver biopsyCirrhotic tissueStaining intensityAmerican Association for Cancer Research annual meetingsLogistic regression modelsDetection of hepatocellular carcinomaDiagnostic of hepatocellular carcinomaEarly detection of hepatocellular carcinomaMulti-cohort studyEvaluating biopsy samplesAnalysis of biopsy tissueAssociated with hepatocellular carcinomaTransforming growth factor-bDevelopment of hepatocellular carcinomaIndependent patient cohortHigh-risk groupGrowth factor BQuantitative IHCPatient cohortBiopsy tissueBiopsy samplesClinical trialsCirrhosisLoss of functiond-Limonene inhibits the occurrence and progression of LUAD through suppressing lipid droplet accumulation induced by PM2.5 exposure in vivo and in vitro
Zhu T, Li Y, Feng T, Yang Y, Zhang K, Gao J, Quan X, Qian Y, Yu H, Qian B. d-Limonene inhibits the occurrence and progression of LUAD through suppressing lipid droplet accumulation induced by PM2.5 exposure in vivo and in vitro. Respiratory Research 2022, 23: 338. PMID: 36496421, PMCID: PMC9741803, DOI: 10.1186/s12931-022-02270-9.Peer-Reviewed Original ResearchConceptsLipid droplet accumulationHuman intervention trialsLung cancer patientsLung adenocarcinomaPM2.5 exposureProgression of LUADDroplet accumulationPulmonary fibrosisIntervention trialsCancer patientsMiR-195Trichrome stainingChinese Clinical Trial RegistrySerum miR-195Clinical Trials RegistryLipid metabolism disordersNormal lung epithelial cellsPotential preventive interventionsNormal lung tissuesDe novo lipogenesis pathwayMasson's trichrome stainingDevelopment of LUADOil red stainingLung epithelial cellsPotential intervention targets
2019
P76 Prospective investigation of pre-diagnostic urinary bisphenol a and phthalates in relation to endometrial cancer risk in the multiethnic cohort (MEC) study
Sarink D, Le Marchand L, Cheng I, Wu A, Franke A, Wilkens L, White K, Yu H, Merritt M. P76 Prospective investigation of pre-diagnostic urinary bisphenol a and phthalates in relation to endometrial cancer risk in the multiethnic cohort (MEC) study. International Journal Of Gynecological Cancer 2019, 29: a101. DOI: 10.1136/ijgc-2019-esgo.138.Peer-Reviewed Original ResearchEndometrial cancer riskEndometrial cancer risk factorsCancer risk factorsMultiethnic Cohort StudyCancer riskCohort studyEndometrial cancerUrinary BPARisk factorsEndometrial cancer incidence ratesHigher body mass indexRole of BPAEndometrial cancer casesPostmenopausal hormone useAge-adjusted incidenceBody mass indexCase-control studyCancer incidence ratesConditional logistic regressionNative Hawaiian womenFrequency of casesRace/ethnicityUrinary bisphenolHormone useOral contraceptives